Cargando…
Intravenously delivered multilineage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy
Perinatal hypoxic ischemic encephalopathy (HIE) results in serious neurological dysfunction and mortality. Clinical trials of multilineage-differentiating stress enduring cells (Muse cells) have commenced in stroke using intravenous delivery of donor-derived Muse cells. Here, we investigated the the...
Autores principales: | Suzuki, Toshihiko, Sato, Yoshiaki, Kushida, Yoshihiro, Tsuji, Masahiro, Wakao, Shohei, Ueda, Kazuto, Imai, Kenji, Iitani, Yukako, Shimizu, Shinobu, Hida, Hideki, Temma, Takashi, Saito, Shigeyoshi, Iida, Hidehiro, Mizuno, Masaaki, Takahashi, Yoshiyuki, Dezawa, Mari, Borlongan, Cesar V, Hayakawa, Masahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217885/ https://www.ncbi.nlm.nih.gov/pubmed/33222596 http://dx.doi.org/10.1177/0271678X20972656 |
Ejemplares similares
-
Human Multilineage-differentiating Stress-Enduring Cells Exert Pleiotropic
Effects to Ameliorate Acute Lung Ischemia–Reperfusion Injury in a Rat
Model
por: Yabuki, Hiroshi, et al.
Publicado: (2018) -
Genetically Engineered Multilineage-Differentiating Stress-Enduring Cells as Cellular Vehicles against Malignant Gliomas
por: Yamasaki, Tomohiro, et al.
Publicado: (2017) -
Therapeutic Potential of Multilineage-Differentiating Stress-Enduring Cells for Osteochondral Repair in a Rat Model
por: Mahmoud, Elhussein Elbadry, et al.
Publicado: (2017) -
Systemic administration of clinical-grade multilineage-differentiating stress-enduring cells ameliorates hypoxic–ischemic brain injury in neonatal rats
por: Ueda, Kazuto, et al.
Publicado: (2023) -
Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial
por: Matsuyama, Nao, et al.
Publicado: (2022)